Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FibroGen, a drug discovery company, has started an open-label, Phase I clinical trial designed to evaluate the safety and tolerability of FG-3019, a fully human monoclonal antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in patients with locally advanced or metastatic pancreatic cancer.
Subscribe to our email newsletter
The study is an open-label, dose-escalation trial expected to enroll up to 18 patients and to test three dose levels of FG-3019 administered via infusion every two weeks. After the second administration of FG-3019, patients will initiate treatment with gemcitabine and erlotinib. Patients will continue on FG-3019 treatment until disease progression as assessed by the response evaluation criteria in solid tumors.
Secondary objectives of the study are to evaluate the activity and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib.
The study is being conducted at two sites: at Stanford University School of Medicine, Stanford, California, where Albert Koong is principal investigator and at Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, where Marc Pipas is principal investigator.